Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor.

Neuropeptide Y (NPY), a 36-amino-acid peptide widely expressed in the brain is involved in many physiological responses, including hypothalamic control of food intake and cardiovascular homeostasis. NPY mediates its effects through binding to the Y1, Y2 and Y5 G-protein-coupled receptors. Little is known of the role of the Y2 receptor in mediating the different NPY effects. We inactivated the Y2 receptor subtype in mice and found that these mice developed increased body weight, food intake and fat deposition. The null mutant mice showed an attenuated response to leptin administration but a normal response to NPY-induced food intake and intact regulation of re-feeding and body weight after starvation. An absence of the Y2 receptor subtype also affected the basal control of heart rate, but did not influence blood pressure. These findings indicate an inhibitory role for the Y2 receptor subtype in the central regulation of body weight and control of food intake.

The cloned guinea pig neuropeptide Y receptor Y1 conforms to other mammalian Y1 receptors.

We have cloned the guinea pig neuropeptide Y (NPY) Y1 receptor and found it to be 92-93% identical to other cloned mammalian Y1 receptors. Porcine NPY and peptide YY (PYY) displayed affinities of 43 pM and 48 pM, respectively. NPY2-36 and NPY3-36 had 6- and 46-fold lower affinity, respectively, than intact NPY. Functional coupling was measured by using a microphysiometer. Human NPY and PYY were equipotent in causing extracellular acidification with EC50 values of 0.59 nM and 0.69 nM, respectively, whereas NPY2-36 and NPY3-36 were about 15-fold and 500-fold less potent, respectively, than NPY. The present study shows that the cloned guinea pig Y1 receptor is very similar to its orthologues in other mammals, both with respect to sequence and pharmacology. Thus, results from previous studies on guinea pig NPY receptors might imply the existence of an additional Y1-like receptor sensitive to B1BP3226.

Turnover of the gastric H+,K(+)-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion.

BACKGROUND & AIMS: The rate of turnover and the effect of inhibition of acid secretion on the turnover of gastric H+,K(+)-adenosine triphosphatase (ATPase) is unknown. The aim of this study was to determine the turnover of the alpha subunit of gastric H+,K(+)-ATPase in rats under control conditions and during inhibition of acid secretion by ranitidine or omeprazole. METHODS: The turnover of the alpha subunit of the ATPase was determined by measuring the loss of incorporated 35S-methionine. This was compared with the rate of recovery of K(+)-stimulated ATPase activity in the omeprazole-treated animals. RESULTS: The half-life of the alpha subunit was 54 hours. A 1-week treatment with omeprazole had no significant effect, but the half-life increased to 125 hours (P < 0.01) after continuous ranitidine infusion. After omeprazole treatment, K(+)-stimulated ATPase activity recovered with a half-time of 15 hours. CONCLUSIONS: The turnover of the gastric ATPase subunit was independent of omeprazole inhibition but was prolonged by ranitidine. The effect of ranitidine suggests that the resting pump in tubulovesicles may turn over more slowly than the stimulated pump in the secretory canaliculus. The rapid recovery of ATPase activity compared with turnover after omeprazole is caused by both H+,K(+)-ATPase synthesis and loss of covalently bound drug.

Coupling of H(+)-K(+)-ATPase activity and glucose oxidation in gastric glands.

The production of 14CO2 from uniformly labeled glucose was shown to account for the entire increase in histamine-stimulated O2 consumption in rabbit gastric glands when no other substrate was added to the medium. The increased production of CO2 was correlated to the increase in O2 consumption and the accumulation of [14C]-aminopyrine (AP) after stimulation with several secretagogues. Inhibitors of H(+)-K(+)-ATPase reduced the secretagogue-induced increase in CO2 production by greater than 90%, showing that the activity of this enzyme was responsible for the greater part of gastric gland metabolism under stimulated conditions. In contrast to AP accumulation, inhibition of CO2 production by omeprazole, an acid-activated inhibitor of the H(+)-K(+)-ATPase, was not reversed by washing. The reversal of AP accumulation after omeprazole treatment and washing was most likely due to a recruitment of residual pumps bordering a nonacidic space, which had not previously been inhibited by omeprazole. These residual pumps slowly generate a pH gradient and hence AP uptake. Adding NH4+ to gastric glands resulted in a concentration-dependent increase of CO2 production up to the maximal stimulated level but without formation of the pH gradient as measured by AP uptake and loss of the omeprazole inhibition of glucose oxidation. As NH4+ can act as a K+ surrogate for H(+)-K(+)-ATPase, and as NH3 is membrane permeant, full stimulation of CO2 production is evidence that the major mechanism of H(+)-K(+)-ATPase activation in situ is an increase in the KCl permeability of the pump membrane.

Specific labelling of gastric H+,K+-ATPase by omeprazole.

Acid secretion is conducted by the parietal cell of the gastric mucosa. The H+,K+-ATPase has been shown to be specifically located to this cell and during recent years been recognized as the gastric proton pump. Omeprazole, a known inhibitor of acid secretion, administered in vivo was found to bind specifically to the H+,K+-ATPase of the rabbit gastric mucosa. A stoichiometry of 2.1 mol radiolabel per mol phosphoenzyme was calculated at total inhibition of the H+,K+-ATPase enzyme activity. In isolated gastric glands prepared from omeprazole-treated animals, the secretagogue-induced increase in oxygen consumption, related to acid secretion, was inhibited to the same level as the H+,K+-ATPase activity. Both the degree of acid secretion inhibition induced by omeprazole and the amount of inhibitor bound to the H+,K+-ATPase were found to be dependent on the stimulation state of the parietal cell. Inhibition of secretion by the H2-receptor blocker ranitidine prior to omeprazole treatment prevented both the inhibition of H+,K+-ATPase and oxygen consumption normally observed with omeprazole and, furthermore, reduced the binding levels of radiolabel to the enzyme. Inhibition of acid secretion by the H+,K+-ATPase inhibitor SCH 28080 totally prevented the binding of radiolabel to the H+,K+-ATPase. The inhibition by omeprazole could be fully reversed in gastric glands and H+,K+-ATPase isolated from omeprazole-treated animals by addition of beta-mercaptoethanol. The major product formed during reactivation was the reduced form of omeprazole, compound H 168/22. Neutralization of the gastric glands in vitro with imidazole totally prevented the inhibitory action of omeprazole. These experiments demonstrate the necessity of acid for the inhibition of gastric acid secretion by omeprazole and the binding of the inhibitor to the H+,K+-ATPase, both in vivo and in vitro, and also the specificity of omeprazole for the H+,K+-ATPase.